Biogen pulls PRIME designation for aducanumab in Europe; Merck closes merger with Acceleron

Following news last week that Biogen received “a negative trend vote” in Europe for its controversial Alzheimer’s drug aducanumab, the company has officially pulled out of the EU’s priority medicines scheme, known as PRIME.

First granted entry into the PRIME program back in May 2016, the EMA

Click to view original post